Doximity price target raised to $63 from $57 at BofA

BofA raised the firm’s price target on Doximity (DOCS) to $63 from $57 and keeps a Neutral rating on the shares after the firm conducted its eleventh survey on advertising spending in the pharmaceutical channel. Overall, this quarter’s survey results were “generally positive” and the firm raised its target to reflect incremental confidence in the near-term growth profile, but were also “not enough to materially change our view,” the analyst tells investors.